Logo image of CRVO

CERVOMED INC (CRVO) Stock Fundamental Analysis

NASDAQ:CRVO - Nasdaq - US15713L1098 - Common Stock - Currency: USD

2.28  -0.05 (-1.94%)

After market: 2.2801 0 (0%)

Fundamental Rating

3

Taking everything into account, CRVO scores 3 out of 10 in our fundamental rating. CRVO was compared to 572 industry peers in the Biotechnology industry. CRVO has a great financial health rating, but its profitability evaluates not so good. CRVO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CRVO has reported negative net income.
CRVO had a negative operating cash flow in the past year.
CRVO had negative earnings in each of the past 5 years.
In the past 5 years CRVO always reported negative operating cash flow.
CRVO Yearly Net Income VS EBIT VS OCF VS FCFCRVO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M -25M

1.2 Ratios

CRVO has a Return On Assets of -24.44%. This is in the better half of the industry: CRVO outperforms 73.71% of its industry peers.
CRVO has a Return On Equity of -26.18%. This is amongst the best in the industry. CRVO outperforms 80.99% of its industry peers.
Industry RankSector Rank
ROA -24.44%
ROE -26.18%
ROIC N/A
ROA(3y)-51.44%
ROA(5y)-52.29%
ROE(3y)-58.53%
ROE(5y)-59.85%
ROIC(3y)N/A
ROIC(5y)N/A
CRVO Yearly ROA, ROE, ROICCRVO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5K 10K 15K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CRVO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRVO Yearly Profit, Operating, Gross MarginsCRVO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80

More info and screens

8

2. Health

2.1 Basic Checks

CRVO has more shares outstanding than it did 1 year ago.
CRVO has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CRVO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRVO Yearly Shares OutstandingCRVO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M 5M
CRVO Yearly Total Debt VS Total AssetsCRVO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

2.2 Solvency

CRVO has an Altman-Z score of 2.18. This is not the best score and indicates that CRVO is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.18, CRVO is in the better half of the industry, outperforming 71.76% of the companies in the same industry.
CRVO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.18
ROIC/WACCN/A
WACCN/A
CRVO Yearly LT Debt VS Equity VS FCFCRVO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M 30M

2.3 Liquidity

CRVO has a Current Ratio of 15.04. This indicates that CRVO is financially healthy and has no problem in meeting its short term obligations.
CRVO has a better Current ratio (15.04) than 89.52% of its industry peers.
CRVO has a Quick Ratio of 15.04. This indicates that CRVO is financially healthy and has no problem in meeting its short term obligations.
CRVO has a Quick ratio of 15.04. This is amongst the best in the industry. CRVO outperforms 89.52% of its industry peers.
Industry RankSector Rank
Current Ratio 15.04
Quick Ratio 15.04
CRVO Yearly Current Assets VS Current LiabilitesCRVO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

CRVO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 66.87%, which is quite impressive.
The Revenue has grown by 116.02% in the past year. This is a very strong growth!
EPS 1Y (TTM)66.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.43%
Revenue 1Y (TTM)116.02%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%27.13%

3.2 Future

CRVO is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -0.15% yearly.
The Revenue is expected to decrease by -24.29% on average over the next years. This is quite bad
EPS Next Y-33.33%
EPS Next 2Y1.11%
EPS Next 3Y-17.43%
EPS Next 5Y-0.15%
Revenue Next Year40.27%
Revenue Next 2Y-11.18%
Revenue Next 3Y-25.99%
Revenue Next 5Y-24.29%

3.3 Evolution

CRVO Yearly Revenue VS EstimatesCRVO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
CRVO Yearly EPS VS EstimatesCRVO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -500 -1K -1.5K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CRVO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRVO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRVO Price Earnings VS Forward Price EarningsCRVO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRVO Per share dataCRVO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

A cheap valuation may be justified as CRVO's earnings are expected to decrease with -17.43% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.11%
EPS Next 3Y-17.43%

More info and screens

0

5. Dividend

5.1 Amount

CRVO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CERVOMED INC

NASDAQ:CRVO (2/21/2025, 8:10:59 PM)

After market: 2.2801 0 (0%)

2.28

-0.05 (-1.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)03-31 2025-03-31/amc
Inst Owners18.17%
Inst Owner Change-44.48%
Ins Owners26.36%
Ins Owner Change0.06%
Market Cap18.81M
Analysts72.86
Price Target24.14 (958.77%)
Short Float %19.45%
Short Ratio2.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.61%
Min EPS beat(2)-30.72%
Max EPS beat(2)13.49%
EPS beat(4)1
Avg EPS beat(4)-12.19%
Min EPS beat(4)-30.72%
Max EPS beat(4)13.49%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)4.29%
Min Revenue beat(2)-37.98%
Max Revenue beat(2)46.57%
Revenue beat(4)3
Avg Revenue beat(4)25.28%
Min Revenue beat(4)-37.98%
Max Revenue beat(4)70.44%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-58.91%
EPS NQ rev (1m)-22.2%
EPS NQ rev (3m)-24.11%
EPS NY rev (1m)-0.8%
EPS NY rev (3m)-15.94%
Revenue NQ rev (1m)-41.69%
Revenue NQ rev (3m)-10.59%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-13.26%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.87
P/FCF N/A
P/OCF N/A
P/B 0.41
P/tB 0.41
EV/EBITDA N/A
EPS(TTM)-1.61
EYN/A
EPS(NY)-1.35
Fwd EYN/A
FCF(TTM)-1.34
FCFYN/A
OCF(TTM)-1.34
OCFYN/A
SpS1.22
BVpS5.53
TBVpS5.53
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.44%
ROE -26.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-51.44%
ROA(5y)-52.29%
ROE(3y)-58.53%
ROE(5y)-59.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.04
Quick Ratio 15.04
Altman-Z 2.18
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.43%
EPS Next Y-33.33%
EPS Next 2Y1.11%
EPS Next 3Y-17.43%
EPS Next 5Y-0.15%
Revenue 1Y (TTM)116.02%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%27.13%
Revenue Next Year40.27%
Revenue Next 2Y-11.18%
Revenue Next 3Y-25.99%
Revenue Next 5Y-24.29%
EBIT growth 1Y-32.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-22.13%
EBIT Next 3Y-42.92%
EBIT Next 5Y-31.23%
FCF growth 1Y24.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.11%
OCF growth 3YN/A
OCF growth 5YN/A